Kineta's VISTA-101 Clinical Trial for KVA12123 in Advanced Solid Tumor Cancer

Monday, 19 August 2024, 06:07

KVA12123 is now understudy in the reopened VISTA-101 clinical trial by Kineta, targeting advanced solid tumor cancer. This enrollment includes a monotherapy arm and a combination arm with Merck’s KEYTRUDA® anti-PD-1 therapy. A total of 30 patients have joined the trial so far, indicating a promising step in cancer treatment innovations.
LivaRava_Technology_Default_1.png
Kineta's VISTA-101 Clinical Trial for KVA12123 in Advanced Solid Tumor Cancer

KVA12123: Advancing Cancer Treatment

Kineta has officially reopened the enrollment for the VISTA-101 clinical trial, focusing on KVA12123 as a potential treatment for patients with advanced solid tumor cancer. This study aims to explore the efficacy of KVA12123 both as a standalone therapy and in synergy with Merck's KEYTRUDA®, an anti-PD-1 therapy.

Trial Structure and Objectives

The VISTA-101 trial features 30 enrolled patients thus far, showcasing the clinical community's eagerness in harnessing innovative treatments. With hopes of achieving significant clinical outcomes, Kineta's approach may change the landscape of cancer care.

  • Clinical Trial Name: VISTA-101
  • Investigational Drug: KVA12123
  • Combination Therapy: KEYTRUDA®
  • Current Enrollment: 30 patients

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most reliable and up-to-date tech news. Stay informed and elevate your tech expertise effortlessly.

Subscribe